v3.26.1

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2026	Dec. 31, 2025
Current Assets
Trade accounts receivable, net	$ 56,295	$ 51,050
Inventory, net	74,234	68,673
Prepaid expenses and other current assets	9,403	9,548
Total current assets	251,682	240,313
Property and equipment, net	5,033	4,945
Operating lease right-of-use assets	21,949	22,112
Goodwill	22,859	22,859
Other assets	85,368	88,078
Other assets	5,122	5,220
Total assets	392,013	383,527
Current Liabilities
Accounts payable	11,467	3,076
Current operating lease liabilities	6,271	6,232
Other accrued liabilities	32,287	33,155
Accrued trade discounts and rebates	45,492	43,253
Accrued returns reserve	18,723	18,969
Other current liabilities	4,353	4,889
Total current liabilities	118,593	109,574
Debt, net of unamortized debt issuance costs, non-current portion	221,224	220,335
Non-current operating lease liabilities	31,058	31,531
Other liabilities	8,127	8,398
Total liabilities	379,002	369,838
Commitments and contingencies (Note 13)
Stockholders' Equity
Preferred stock—par value $0.0001, 25,000,000 shares authorized and no shares issued and outstanding as of March 31, 2026 and December 31, 2025	0	0
Common stock—par value $0.0001, 350,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 172,558,783 and 166,215,410 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	18	17
Additional paid in capital	682,090	685,004
Accumulated deficit	(669,073)	(671,307)
Accumulated other comprehensive loss	(24)	(25)
Total stockholders' equity	13,011	13,689
Total liabilities and stockholders' equity	392,013	383,527
Cash and cash equivalents	$ 111,750	$ 111,042

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Xeris Biopharma Holdings, Inc. 10-Q